Please login to the form below

Not currently logged in
Email:
Password:

Eisai takes Almirall's cinitapride to China

Almirall SA has signed an agreement with Eisai Co Ltd granting Eisai the marketing rights to Almirall's gastroprokinetic agent cinitapride in China

Almirall SA has signed an agreement with Eisai Co Ltd granting Eisai the marketing rights to Almirall's gastroprokinetic agent cinitapride in China. The Spain- and Japan-headquartered companies have common interests in the gastrointestinal area; as well as Almirall's antihistamine Ebastine, which Eisai has made available in China since 2001, the partners have other shared projects in the market.

Currently marketed in Spain and Mexico under the names Cidine, Blaston and Pemix, cinitapride, developed by Almirall, is an orthopramide with prokinetic activity on the gastrointestinal tract, which blocks the presynaptic serotonin receptors and has antidopaminergic activity. Its marked procholinergic action improves gastrointestinal motility.

In Spain cinitapride is indicated for treating mild to moderate dysmotility-type dyspepsia and as an adjunctive therapy for gastroesophageal reflux disease (GERD) in patients for whom proton pump inhibitor (PPI) therapy has been shown to be insufficient.

Almirall already has a significant presence in Japan, Korea and Australia. Partnering with Eisai to market cinitapride in China is another aspect of Almirall's strategy to expand its presence in the Asian market through the distribution of its main R&D medicines.

This is a key focus for Almirall, which dedicates 15 per cent of its human resources to R&D and 20 per cent of its total revenue to drug discovery, and — through its own drugs and licences — has a presence in more than 100 countries worldwide.

19th April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics